Literature DB >> 21251460

Effectiveness of recombinant activated factor VII in haemorragic cancer-related disseminated intravascular coagulation: a case report.

Matteo Giorgi Pierfranceschi1, Davide Imberti, Sergio Orlando, Daniele Vallisa, Emanuele Michieletti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21251460      PMCID： PMC3136602          DOI： 10.2450/2010.0053-10

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  10 in total

1.  Platelet-dependent action of high-dose factor VIIa.

Authors:  Maureane Hoffman; Douglas M Monroe; Harold R Roberts
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

2.  Successful outcome of DIC and life-threatening bleeding in a toddler with neuroblastoma treated with recombinant activated factor VII.

Authors:  Emmanouil S Hatzipantelis; Nikolaos Gombakis; Vasiliki Sidi; Evgenia Papakonstantinou; Dimitrios E Koliouskas
Journal:  Intern Emerg Med       Date:  2008-02-09       Impact factor: 3.397

3.  Mechanism of factor VIIa-dependent coagulation in hemophilia blood.

Authors:  Saulius Butenas; Kathleen E Brummel; Richard F Branda; Sara G Paradis; Kenneth G Mann
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

4.  Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.

Authors:  M C Poon; C Demers; F Jobin; J W Wu
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

Review 5.  Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.

Authors:  Massimo Franchini; Franco Manzato; Gian Luca Salvagno; Martina Montagnana; Marco Zaffanello; Giuseppe Lippi
Journal:  Semin Thromb Hemost       Date:  2010-02-18       Impact factor: 4.180

6.  Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation.

Authors:  Sabah Sallah; Aisha Husain; Nam P Nguyen
Journal:  Blood Coagul Fibrinolysis       Date:  2004-10       Impact factor: 1.276

7.  Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.

Authors:  A D Shapiro; G S Gilchrist; W K Hoots; H A Cooper; D A Gastineau
Journal:  Thromb Haemost       Date:  1998-11       Impact factor: 5.249

8.  Blood transfusion, independent of shock severity, is associated with worse outcome in trauma.

Authors:  Debra L Malone; James Dunne; J Kathleen Tracy; A Tyler Putnam; Thomas M Scalea; Lena M Napolitano
Journal:  J Trauma       Date:  2003-05

9.  Recombinant activated factor VII for the treatment of life-threatening haemorrhage.

Authors:  John W Eikelboom; Robert Bird; David Blythe; Luke Coyle; Eng Gan; Michael Harvey; James Isbister; Michael Leahy; David McIlroy; Farhad Rahimpanah; Sundra Ramanthan; Simone Strasser; Chris Ward; Andrew Watts; Simon Towler; Qilong Yi
Journal:  Blood Coagul Fibrinolysis       Date:  2003-12       Impact factor: 1.276

10.  Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.

Authors:  Massimo Franchini; Giuseppe Lippi; Franco Manzato
Journal:  Thromb J       Date:  2006-02-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.